<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202835</url>
  </required_header>
  <id_info>
    <org_study_id>CTTC1901</org_study_id>
    <secondary_id>OZM-099</secondary_id>
    <nct_id>NCT04202835</nct_id>
  </id_info>
  <brief_title>ATG Plus PTCy vs ATG for CGVHD Prophylaxis</brief_title>
  <official_title>A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cell Therapy Transplant Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ozmosis Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus
      post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft
      versus host disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute leukemia or myelodysplastic syndrome will be randomized to receive, or
      not receive, post transplant cyclophosphamide in addition to anti-thymocyte globulin.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized pilot trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Registration of 80 patients within twenty four months</measure>
    <time_frame>24 months</time_frame>
    <description>Registration will be documented by the Clinical Research Organization (Ozmosis Research Inc.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CRFS</measure>
    <time_frame>27 months</time_frame>
    <description>Chronic graft versus host disease free- and relapse-free survival (CRFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GRFS</measure>
    <time_frame>27 months</time_frame>
    <description>Graft versus host disease-, and relapse-, free survival (GRFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>27 months</time_frame>
    <description>Survival (dead/alive) at 100 days for each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete data collection</measure>
    <time_frame>27 months</time_frame>
    <description>The Clinical Research Organization (Ozmosis Research Inc.) will document completeness of data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of study</measure>
    <time_frame>27 months</time_frame>
    <description>The sponsor (McMaster University) and the Clinical Research Organization (Ozmosis Research Inc.) will compare actual total trial costs in Canadian dollars at trial completion (at completion of outcomes analysis and report) with expected costs as determined for the trial budget.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Myelodysplasia</condition>
  <condition>Chronic Graft-versus-host-disease</condition>
  <arm_group>
    <arm_group_label>ATG/PTCy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Post Transplant Cyclophosphamide</description>
    <arm_group_label>ATG/PTCy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Thymocyte globulin (rabbit)</intervention_name>
    <description>Anti-Thymocyte Globulin (rabbit, Thymoglobulin)</description>
    <arm_group_label>ATG</arm_group_label>
    <arm_group_label>ATG/PTCy</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant is aged between 16 and 70

          2. The participant has either

               1. Acute myeloid leukemia in remission, or

               2. Myelodysplastic syndrome

          3. The participant will receive a Hematopoietic Progenitor Cell graft obtained by
             apheresis (&quot;HPC, Apheresis&quot;)

          4. The participant has a related or unrelated donor, who is either fully Major
             Histocompatibility Complex (MHC)-matched with the recipient at Human Leukocyte Antigen
             (HLA)-A, B, C and DRB1 or is 1-antigen or 1-allele mismatched at these loci.

          5. The participant meets the transplant centre's criteria for transplantation, using
             either myeloablative or non-myeloablative or reduced intensity conditioning .

          6. The participant has good performance status (Karnofsky ≥60%)

          7. The participant is able to understand and sign the informed consent form

          8. Ability and willingness to comply with study procedures and schedule, in the
             Investigator's opinion.

        Exclusion Criteria:

          1. The participant is HIV antibody positive

          2. The participant has a hypersensitivity to rabbit proteins or Thymoglobulin®
             pharmaceutical excipients, glycine or mannitol

          3. The participant has active or chronic infection (i.e. infection requiring oral or IV
             therapy)

          4. The participant (if female and of childbearing potential) is pregnant or
             breast-feeding at the time of enrollment

          5. The participant (if female and of childbearing potential) does not agree to use an
             adequate contraceptive method from the time of enrollment until a minimum of one year
             following transplant

          6. The participant (if male and fertile) does not agree to use an adequate contraceptive
             method from the time of enrollment until a minimum of one year following transplant2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irwin R Walker, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Kleiboer</last_name>
    <phone>1 416 634 8322</phone>
    <email>sarah.kleiboer@ozmosisresearch.com</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post transplant cyclophosphamide</keyword>
  <keyword>anti-thymocyte globulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

